July 11, 2020

Volume X, Number 193

July 10, 2020

Subscribe to Latest Legal News and Analysis

July 09, 2020

Subscribe to Latest Legal News and Analysis

Supreme Court Rejects Government’s Expansive View of FCA Liability but Endorses Implied Certification Theory (with Limits)

On June 16, 2016, the Supreme Court of the United States rendered a unanimous decision in the highly anticipated False Claims Act (“FCA”) case of Universal Health Services, Inc. v. United States ex rel. Escobar.[1] In its decision, the Court endorsed expanding the scope of potential liability under the federal False Claims Act (“FCA”) in certain circumstances but expressly rejected the position of the government and a lower court that every undisclosed violation of a statute, regulation, or contractual term is a basis for multiple damages and civil penalties under the FCA. The Court’s decision is significant for health care providers and suppliers that submit claims to federally funded health care programs, including Medicare and Medicaid, because the FCA remains one of the federal government’s primary enforcement tools. The Court concluded that an implied false certification of compliance—a statement in the claim or an omission from a claim that renders the claim misleading—can be actionable under the FCA. The Court also rejected the holding of several courts that FCA liability reaches only those issues where a claimant has expressly certified that it has complied with a specific term.

Background of the Litigation and the First Circuit’s Decision

The Universal Health case arose after a Medicaid beneficiary received mental health services and medication at a facility in Massachusetts and subsequently died. The patient’s family was told afterward that many of the practitioners who saw the beneficiary either lacked the appropriate credentials to treat her or were not properly licensed under state law. The patient’s family ultimately filed a qui tam action, alleging that, because the facility had submitted Medicaid reimbursement claims using codes that implied that the services were performed by qualified and licensed staff, the claims were false claims under the FCA. The district court dismissed the action on the ground that the facility had not violated a condition for payment in the relevant regulations. The U.S. Court of Appeals for the First Circuit reversed this part of the decision, ruling that any time a provider submits a claim, it impliedly certifies its compliance with all program requirements, whether or not expressly stated in the claim.

The Supreme Court’s Ruling and Its Impact on Health Care Providers and Suppliers

The Supreme Court held that FCA liability can be based on an implied false certification when either the ordinary inference from a representation in the claim, or an omission in the claim, makes the representations in the claim misleading with respect to the goods or services provided. In the Court’s view, half-truths in a claim for reimbursement from a government program such as Medicare or Medicaid is just as actionable as an outright lie if the failure to disclose noncompliance with a statute, regulation, or contract term makes those representations misleading half-truths.

Nevertheless, the Court did not agree with the expansive view proffered by the First Circuit or with the government that all breaches or violations result in FCA liability. The Court reiterated that the FCA is not an all-purpose anti-fraud statute, and that not every omission, regulatory violation, or contract breach can result in the fines and multiple damages called for in the FCA. Instead, the Court confirmed that FCA liability is still limited to situations where the noncompliance is material to inducing the government to pay a claim, and that the requirement of materiality is “demanding.”

What is a material element of a claim is still a case-by-case determination; indeed, the Court noted that just because the government designates a term as a condition of payment does not automatically make that term material. While the Court did not establish a bright line between permissible conduct and FCA violations, there are some factors that providers and suppliers to government programs should consider:

  • If the government knew of an undisclosed fact, would it likely not pay the claim?

  • Has the government suffered any demonstrable loss?

  • Has the government consistently denied payment of claims (or paid claims) when it knows that the provider or supplier is not in compliance with a particular statutory, regulatory, or contract term?

  • If the claims are reviewed by an agency’s contracting officer or other official, was the deliverable work approved?


Although the Court has resolved the question of whether or not an implied false certification can result in a violation of the FCA, it remains to be seen in future cases and in the actions of enforcement agencies how elastic the concept of materiality will be. Health care entities should continue to resist vigorously efforts by the government and qui tam relators to use the FCA as a weapon against what are in reality nothing more than minor and immaterial regulatory missteps. Universal Health demonstrates that defenses against this overreach remain alive and well.

[1] 579 U.S. __, No. 15-7 (June 16, 2016), available here.

©2020 Epstein Becker & Green, P.C. All rights reserved.National Law Review, Volume VI, Number 172


About this Author

Stuart Gerson, Health Care Attorney, Epstein Becker Law Firm
Member of the Firm

STUART M. GERSON is a Member of the Firm in the Litigation and Health Care & Life Sciences practices, in the firm's Washington, DC, and New York offices. Much of Mr. Gerson's practice has been centered on providing representation to clients in the health care industry (including insurers, hospitals, pharmaceutical manufacturers, managed care providers, and private equity funds, among others). He has extensive experience litigating cases involving the cybersecurity of health care information, trade secrets, and other confidential data as well as civil...

George Breen, Health Care Attorney, Epstein Becker Law Firm

GEORGE B. BREEN is a Member of the Firm in the Health Care and Life Sciences and Litigation practices. He is Chair of the firm's National Health Care and Life Sciences Practice Steering Committee and a member of the firm's Board of Directors.

Mr. Breen:

  • Defends clients undergoing investigation for health care fraud by the Department of Justice, the Department of Health and Human Services Office of the Inspector General, and other state and federal governmental authorities
  • Serves as defense counsel in connection with False Claims Act cases (including qui tam litigation)
  • Conducts compliance investigations and advises clients on compliance, reimbursement, and health regulatory issues
  • Represents MCOs, HMOs, nursing homes, home health agencies, health care providers, manufacturers and suppliers before courts and administrative tribunals at the federal and state level, including challenges to regulatory actions and disputes under government contracts
Robert E. Wanerman, Epstein Becker Green, Health Lawyer

ROBERT E. WANERMAN is a Member of the Firm in the Health Care and Life Sciences practice, in the Washington, DC, office of Epstein Becker Green. His practice concentrates on regulatory, reimbursement, and compliance matters affecting health care manufacturers, service providers, and investors in health care organizations. He has extensive experience counseling clients in matters arising under the Medicare and Medicaid programs, administrative law and procedure, the False Claims Act, clinical research rules, grant administration rules, the Anti-Kickback and Stark laws,...

Jonah D. Retzinger, Epstein Becker Green, Health Care Fraud Lawyer, Industry Trends Policy Attorney

JONAH D. RETZINGER is an Associate in the Health Care and Life Sciences practice, in the firm's Washington, DC, office.

Mr. Retzinger:

  • Represents health care companies and health care providers in a variety of litigation matters, including matters arising under the federal False Claims Act

  • Assists health care companies and health care providers with government investigations concerning alleged violations of federal and state health care fraud and abuse laws

  • ...